GEOVAX LABS, INC. Net Fee Amt
GEOVAX LABS, INC. (GOVX) had Net Fee Amt of $738.85 as of 2026-09-15, per its S-1 filed 2026-09-17.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-17
- 2026-09-15: Net Fee Amt $738.85.
- 2026-04-13: Net Fee Amt $204.83.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-15 | $738.85 S-1 · filed 2026-09-17 |
| 2026-04-13 | $204.83 S-1 · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |